Fool.com
The World's Greatest Investing Community
Results 51 - 60 of 428 : Previous 2 3 4 5 6 7 8 9 10 Next
4-Star Stocks Poised to Pop: Amgen
Market-trouncing returns could be written in this 4-Star.
The FDA advisory panel gives Savient's Krystexxa a passing grade.
The agency weighs in (unhappily) on follow-on biologics.
Analysts Say This Stock Is a Double
Is now the time to dive into penny stocks?
Merck's heart failure drug fails.
Sell before adding? I guess if you have to.
The lid on the black box might be coming off.
Going Up for All the Wrong Reasons
Mystery bidder identified. So what?
Who's fallen hardest? Who can bounce highest?
ViroPharma gets its day in FDA court.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK